The drug candidate, olezarsen, showed statistically significant reduction in levels of triglyceride compared to placebo, as well as showed a 100% reduction in inflammation of the pancreas.
Tag Archive for: Inflammation
The latest deals will see the biotech division of the Samsung Group produce biosimilar products ranging from oncology and inflammation to immunotherapy in the period to 2029 at its new Plant 4 in South Korea.
Following a May 2023 settlement with Amgen, J&J has also signed an agreement with Teva and Alvotech, allowing their Stelara biosimilar to enter the U.S. no later than February 21, 2025.
A Delaware jury ruled in favor of Gilead Sciences, finding that the company’s HIV prevention medicines Truvada and Descovy do not infringe on U.S. government patents and that the patents themselves are invalid in the first place. The company also announced it was acquiring private San Diego biotech XinThera.
Analysts said the development marked a key milestone for Intellia and the broader gene editing field, as it points to FDA’s increased willingness to allow trials for gene therapies.
Drugmaker AstraZeneca said on Tuesday that its asthma drug Fasenra failed to meet one of two main goals of a late-stage study assessing the treatment’s benefits in a chronic allergic condition that causes difficulty in swallowing.
Pfizer signaled its interest in longevity research through a new partnership -and a $500,000 investment – in a decentralized drug development program driven by VitaDAO.
On Thursday, Pfizer announced the U.S. Food and Drug Administration granted the company’s combinatorial therapeutic ervogastat/clesacostat Fast Track Designation. The therapeutic combo is intended for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis.